Filing Analysis
Cellectar Biosciences, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026, and provided a general corporate update.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes the release of Q2 2026 financial results and a corporate update via press release (Exhibit 99.1).
Cellectar Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on July 7, 2026, where shareholders approved several key proposals including the election of directors and an increase in shares available under the 2021 Stock Incentive Plan.
🚩 Red Flags
- Approval of warrant exercises involving a significant number of potential new shares (up to ~39.6M) may lead to future dilution for existing shareholders.
📋 Key Facts
- Annual Meeting held on July 7, 2026.
- Stockholders approved increasing the 2021 Stock Incentive Plan by 2,000,000 shares.
- Andrew Gu and Douglas J. Swirsky were elected to Class III director positions for three-year terms.
- Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026.
- Stockholders approved the exercise of warrants to purchase up to 39,618,078 shares of common stock.
Cellectar Biosciences announced that Director Stefan D. Loren will not stand for reelection and will transition to a paid consulting role. He is being replaced on the board and audit committee by Andrew Gu, an analyst from Nantahala Capital Management, pursuant to a board designation agreement from a recent financing deal.
🚩 Red Flags
- The board appointment is a direct result of a financing side letter, indicating significant influence by a single institutional investor (Nantahala).
- The departing director is receiving a consulting contract and additional stock options, which can be viewed as a non-standard severance-style arrangement for a board member.
📋 Key Facts
- Dr. Stefan D. Loren notified the board on May 17, 2026, of his intent not to stand for reelection at the 2026 annual meeting.
- The company entered into a one-year consulting agreement with Dr. Loren effective July 8, 2026, paying $15,000 per quarter plus a grant of 15,000 stock options.
- Andrew Gu was appointed as a Class III director and member of the Audit Committee effective May 18, 2026.
- Mr. Gu's appointment was mandated by a 'Board Designation Side Letter' with Nantahala Capital Management, LLC, following a securities purchase agreement dated May 4, 2026.
- Andrew Gu has been an analyst at Nantahala Capital Management since June 2021, focusing on biotechnology investments.
Cellectar Biosciences reported its financial results for the first quarter ended March 31, 2026, and provided a corporate update. The information was disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The report covers the fiscal quarter ended March 31, 2026.
- The filing was submitted on May 14, 2026, under Item 2.02.
- A corporate update was provided alongside the financial results in Exhibit 99.1.
Cellectar Biosciences announced a $35 million financing package through a registered direct offering and concurrent private placement of shares and milestone-based warrants. The capital will fund a Phase 3 trial for iopofosine I 131 following positive Phase 2b data in Waldenström macroglobulinemia.
🚩 Red Flags
- Massive potential dilution: The 39.6 million milestone warrants represent nearly 5x the post-offering outstanding share count of 7,975,069.
- Related-party transaction: Executive management team participated directly in the private placement.
- Board designation rights: A single institutional investor (Nantahala) gained the right to appoint a director.
📋 Key Facts
- Gross proceeds of approximately $35 million before fees and expenses.
- Issuance of 1,618,053 registered shares and 2,116,887 unregistered shares at $2.88 per share (management) and implied similar rates for investors.
- Issuance of 9,471,086 Pre-Funded Warrants and 39,618,078 Milestone Warrants across three tranches (A, B, and C).
- Milestone warrants are tied to clinical/regulatory events: Phase 3 initiation (Tranche A), NDA acceptance (Tranche B), and NDA approval (Tranche C).
- Nantahala Capital Management granted the right to designate one independent director to the Board.
- Reported 83.6% Overall Response Rate (ORR) and 61.8% Major Response Rate (MRR) from Phase 2b CLOVER WaM trial.
Cellectar Biosciences reported its financial results for the full year ended December 31, 2025, and provided a general corporate update via a press release.
📋 Key Facts
- The report was filed on March 4, 2026, covering the fiscal year ended December 31, 2025.
- The company furnished a press release as Exhibit 99.1.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
Cellectar Biosciences, Inc. filed an 8-K to announce its third quarter 2025 financial results and provide a corporate update as of November 13, 2025.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Filing date: November 13, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and a corporate update.
Cellectar Biosciences entered into inducement letters to encourage holders of existing warrants to exercise them for cash, resulting in approximately $5.8 million in gross proceeds. The company issued new 'Inducement Warrants' (Series I and II) as an incentive for this early exercise.
🚩 Red Flags
- Warrant inducement indicates a need for immediate liquidity/cash infusion.
- Potential future dilution from both the exercised shares and the new Inducement Warrants.
- Cash runway is projected only through Q3 2026, indicating ongoing capital requirements.
📋 Key Facts
- Closed transaction on October 8, 2025.
- Total aggregate gross proceeds: approximately $5.8 million.
- Existing warrants exercised at $5.25 per share to purchase 1,048,094 shares of common stock.
- New Inducement Warrants issued at an exercise price of $6.00 per share.
- Series I Inducement Warrants expire October 8, 2030; Series II Inducement Warrants expire April 8, 2027.
- Company anticipates cash runway into the third quarter of 2026 based on current estimates and net proceeds.
Cellectar Biosciences announced that the EMA's Scientific Advice Working Party (SAWP) advised that a Conditional Marketing Authorization (CMA) filing for iopofosine I 131 in post-BTKi refractory Waldenstrom macroglobulinemia is acceptable. This regulatory milestone could lead to commercial availability in 30 EU countries as early as 2027.
🚩 Red Flags
- No guarantee of final CMA approval; EMA may still find data insufficient or require additional trials.
- Scientific advice is legally non-binding and does not determine safety/efficacy sufficiency.
- Historical precedent noted: companies with positive SAWP advice have ultimately failed to obtain marketing authorization.
📋 Key Facts
- EMA's SAWP advised that filing for CMA for iopofosine I 131 is acceptable for the post-BTKi refractory WM patient population.
- The proposed patient population aligns with >70% of patients enrolled in the CLOVER WaM Phase 2 study.
- If approved, commercial availability in EMA-represented countries could begin as early as 2027.
- Estimated unmet medical need in Europe: 35,000 to 45,000 patients with WM.
Cellectar Biosciences, Inc. filed an 8-K to announce its second quarter 2025 financial results and provide a corporate update as of August 14, 2025.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Filing date: August 14, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results and a corporate update.
- Company is listed on the Nasdaq Capital Market under ticker CLRB.
Cellectar Biosciences is providing updates regarding a proposed offering of securities to fund clinical studies for its lead candidates, CLR 125 and CLR 225. The company aims to initiate Phase 1b trials in the second half of 2025, contingent upon securing additional financing.
🚩 Red Flags
- Clinical trials (CLR 125 and CLR 225) are explicitly contingent upon the company's ability to obtain additional financing.
- Historical mention of fatalities in patients post-treatment with iopofosine (though noted as part of clinical context).
📋 Key Facts
- Proposed offering intended to provide capital for operating expenses and clinical studies.
- Planned Phase 1b study for CLR 125 (iodine-125) in triple-negative breast cancer (TNBC) scheduled for H2 2025, subject to financing.
- Planned Phase 1 imaging/dose escalation study for CLR 225 (actinium-225) scheduled for H2 2025, subject to financing.
- CLR 125 preclinical data showed high tumor uptake in TNBC models with no observed end-organ toxicity.
- CLR 225 preclinical data showed dose-dependent tumor volume reduction in pancreatic adenocarcinoma models.
- The company reported historical clinical data for iopofosine, including a 58.2% major response rate in the CLOVER-WaM study.
Cellectar Biosciences, Inc. has implemented a one-for-thirty (1-for-30) reverse stock split of its common stock effective June 24, 2025. The action was executed via an amendment to the company's Second Amended and Restated Certificate of Incorporation.
🚩 Red Flags
- Reverse stock split (often used to boost share price to meet exchange listing requirements)
- Potential signal of impending delisting risk or significant downward pressure on equity value
📋 Key Facts
- Effective date of the reverse split: June 24, 2025.
- Split ratio: One-for-thirty (1-for-30).
- No fractional shares will be issued; instead, fractional interests will be liquidated and proceeds distributed to shareholders at prevailing market prices.
- The action was completed by amending the Second Amended and Restated Certificate of Incorporation.
Cellectar Biosciences, Inc. announced that stockholders approved a 1-for-30 reverse stock split on June 13, 2025. The split is scheduled to become effective at 12:01 a.m. ET on June 24, 2025.
🚩 Red Flags
- Reverse stock split (typically used to boost share price to meet exchange listing requirements or avoid delisting).
- High consolidation ratio (1-for-30) often indicates significant downward pressure on the stock price prior to the split.
📋 Key Facts
- Ratio of reverse stock split is 1-for-30.
- Effective time: 12:01 a.m. ET on Tuesday, June 24, 2025.
- Every 30 shares previously outstanding will be converted into one share.
- Fractional shares will be paid out in cash instead of issued as stock.
- Outstanding stock options, warrants, and preferred stock conversion ratios will adjust proportionately.
Cellectar Biosciences, Inc. held its 2025 Annual Meeting of Stockholders on June 13, 2025, where shareholders approved a proposal for a reverse stock split with a ratio between 1:10 and 1:30.
🚩 Red Flags
- Approval of a reverse stock split (1:10 to 1:30) is often used to regain compliance with minimum bid price requirements for exchange listing, signaling potential delisting risk or extreme share price dilution/volatility.
📋 Key Facts
- Annual Meeting held on June 13, 2025.
- Stockholders approved Proposal No. 3: A reverse stock split of common stock at a ratio between 1:10 and 1:30, to be determined by the Board.
- James V. Caruso and Frederick W. Driscoll were elected to Class II director positions (three-year terms).
- Stockholders ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2025.
- Stockholders approved executive compensation on a non-binding advisory basis.
Cellectar Biosciences has entered into warrant exercise inducement letters to encourage the immediate exercise of 8,301,322 outstanding warrants at a significantly reduced price of $0.3041 per share. This move is designed to accelerate cash inflow but will result in substantial equity dilution for existing shareholders.
🚩 Red Flags
- Significant equity dilution: The issuance of over 8.3 million shares at a low price point ($0.3041) will dilute existing shareholders.
- Warrant Inducement: Companies typically use these 'sweeteners' when they are facing liquidity constraints and need immediate cash to fund operations.
📋 Key Facts
- Total shares involved: 8,301,322 common stock shares.
- Reduced exercise price: $0.3041 per share.
- Warrants were originally issued on June 5, 2020, October 25, 2022, and July 21, 2024.
- The transaction is expected to close on or about June 6, 2025.
- Issuance of shares will be done under Section 4(a)(2) exemption from registration requirements.
Cellectar Biosciences, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025, and provided a corporate update via press release.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes an announcement of financial results and a corporate update (Exhibit 99.1).
- Company is listed on the Nasdaq Capital Market under ticker CLRB.
Cellectar Biosciences announced on April 30, 2025, that it is exploring strategic alternatives and has engaged Oppenheimer & Co. Inc. as its exclusive financial advisor to assist in this evaluation.
🚩 Red Flags
- Exploration of 'strategic alternatives' is often a precursor to a sale, merger, or restructuring due to liquidity or operational challenges.
📋 Key Facts
- Company plans to explore 'strategic alternatives' as of April 30, 2025.
- Hired Oppenheimer & Co. Inc. as the exclusive financial advisor for the strategic evaluation process.
Cellectar Biosciences announced amendments to executive employment agreements and the adoption of amended and restated By-Laws. The changes include updated severance packages for the CEO and COO triggered by change in control events.
🚩 Red Flags
- Significant increase in severance obligations (up to 24 months) triggered specifically by 'change in control' events.
- Reduction of quorum requirements to 1/3, which can make it easier for minority groups to pass resolutions or facilitate certain corporate actions.
📋 Key Facts
- On March 12, 2025, the Board approved amendments to employment agreements for President/CEO James V. Caruso and COO Jarrod Longcor.
- Severance for Mr. Caruso: 24 months of base salary, target bonus, and benefit continuation upon qualifying termination following a change in control.
- Severance for Mr. Longcor: 18 months of base salary and benefits continuation upon qualifying termination following a change in control.
- The Board adopted Amended and Restated By-Laws effective March 11, 2025.
- By-Law changes include reducing the quorum requirement for stockholder meetings from a majority to one-third (1/3) of shares present or represented by proxy.
Cellectar Biosciences, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024, and provided a corporate update via press release.
📋 Key Facts
- Reporting period: Fiscal year ended December 31, 2024.
- Filing date: March 13, 2025.
- The filing includes an earnings press release (Exhibit 99.1) and a corporate update.
Cellectar Biosciences received a notice from Nasdaq stating it is in violation of the minimum bid price requirement (Rule 5550(a)(2)). The company has 180 days to regain compliance, with a deadline of July 29, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq.
- Requirement to potentially execute a reverse stock split to regain compliance.
- Stock price currently trading below the $1.00 minimum requirement.
📋 Key Facts
- Received notice from Nasdaq on January 30, 2025.
- Violation: Failure to maintain a minimum bid price of $1.00 per share.
- Compliance deadline: July 29, 2025 (180-day window).
- Potential remedy mentioned: A reverse stock split may be required to meet compliance requirements if the market value criteria are met.
Cellectar Biosciences issued an 8-K to furnish a press release regarding its upcoming presentation of 2025 strategic initiatives at the Biotech Showcase during the JP Morgan Healthcare Conference.
📋 Key Facts
- The company will present its 2025 strategic initiatives at the Biotech Showcase.
- The announcement is tied to the JP Morgan Healthcare Conference schedule.
- Filing date: January 14, 2025; Event date: January 12, 2025.
Cellectar Biosciences is undergoing a massive 60% workforce reduction and strategic pivot following FDA feedback regarding its confirmatory study requirements for iopofosine I 131. The company is shifting focus toward actinium-225 and iodine-125 based programs to extend its cash runway into Q3 2025.
🚩 Red Flags
- Massive 60% reduction in workforce indicates significant distress or radical change in business model.
- FDA feedback requires a more complex/expensive confirmatory study (PFS data) than previously anticipated for iopofosine I 131.
- Cash runway only extends to Q3 2025, indicating potential liquidity needs within the next 9 months.
- Strategic abandonment of primary asset focus (iopofosine I 131) in favor of earlier-stage preclinical/early clinical assets.
📋 Key Facts
- Workforce reduction of approximately 60% of total headcount.
- Expected annual operating cost savings: ~$7.5 million.
- Estimated one-time severance costs: ~$1.7 million (to be recorded in Q4 2024 and Q1 2025).
- Strategic pivot from iopofosine I 131 toward CLR 121225 (actinium-225) and CLR 121125 (iodine-125).
- Planned IND applications for new programs in H1 2025.
- Cash runway expected to extend into the third quarter of 2025.
Cellectar Biosciences, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2024, and provided a general corporate update.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024
- Filing date: November 18, 2024
- The filing includes the Q3 2024 financial results and a corporate update via press release (Exhibit 99.1).
Cellectar Biosciences filed an 8-K to provide a revised consent from its independent auditor for an amended Annual Report (Form 10-K/A). The revision was necessary because the previous consent inadvertently omitted references to several registration statements.
🚩 Red Flags
- Administrative error regarding auditor consent for registration statements (though non-financial in nature).
📋 Key Facts
- The filing is related to an amended Form 10-K/A filed on October 29, 2024, for the fiscal year ended December 31, 2023.
- The error was described as an 'inadvertent omission' regarding auditor consent references in Exhibit 23.1.
- The omitted items were several Form S-1 and Form S-3 registration statements (File Nos. 333-208638, 333-214310, etc.).
- The company explicitly states that the Revised Consent does not change any previously reported financial results or other disclosures in the Form 10-K.
Cellectar Biosciences announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following a period of non-compliance regarding the timely filing of its Form 10-Q. The company issued this 8-K to formally communicate this regulatory resolution.
🚩 Red Flags
- Previous non-compliance with Nasdaq listing rules regarding financial reporting timelines (implied by the resolution).
📋 Key Facts
- The Company received a letter from Nasdaq, Inc. confirming it has regained compliance with Nasdaq Listing Rule 5250(c)(1).
- Compliance relates specifically to the timely filing of Form 10-Q reports.
- Filing date: November 1, 2024.
Cellectar Biosciences received a notice from Nasdaq regarding non-compliance with periodic filing requirements due to delays in filing its 10-Q for the quarter ended June 30, 2024. This delay is driven by the need to restate multiple years of historical financial statements due to accounting treatment re-evaluations of warrants issued in October 2022.
🚩 Red Flags
- Delisting notice (Nasdaq non-compliance with periodic reporting).
- Material restatement of multiple years of financial statements (2022 and 2023) plus several interim periods.
- Potential for significant impact on equity/capital structure due to warrant accounting re-evaluation.
📋 Key Facts
- Received notice from Nasdaq on August 20, 2024, for failure to satisfy Nasdaq Listing Rule 5250(c)(1).
- The company is delaying its Form 10-Q for the quarter ended June 30, 2024.
- Restatement required for audited financial statements for fiscal years ended Dec 31, 2023, and Dec 31, 2022.
- Restatement required for unaudited interim condensed consolidated financial statements for periods ending March 31, 2023, June 30, 2023, Sept 30, 2023, and March 31, 2024.
- The delay is due to re-evaluating the accounting treatment of warrants issued in October 2022.
- The company expects the restatement process to take approximately six weeks.
Cellectar Biosciences, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2024, and provided a general corporate update.
📋 Key Facts
- Reported financial results for the quarter ended June 30, 2024.
- Issued a corporate update alongside the earnings release on August 13, 2024.
- The filing is primarily an announcement of quarterly performance (Item 2.02).
Cellectar Biosciences has determined that its previously issued financial statements for fiscal years 2022 and 2023, as well as interim periods through March 31, 2024, should no longer be relied upon. The restatement is driven by a re-evaluation of the accounting treatment for warrants issued in October 2022 following the engagement of new auditors.
🚩 Red Flags
- Requirement to restate multiple years of audited and unaudited financial statements.
- Potential material weakness in internal controls over financial reporting (ICFR) related to warrant accounting.
- Delayed filing of upcoming 10-Q report.
- Risk of Nasdaq delisting mentioned in forward-looking statements due to potential non-compliance with filing deadlines.
📋 Key Facts
- Non-reliance periods include FY 2022 and FY 2023 (10-Ks) and quarterly periods ending March 31, 2024.
- The error stems from the accounting treatment of warrants issued in October 2022 financing.
- The company engaged Deloitte & Touche LLP as its new independent auditor in July 2024.
- The company anticipates delaying the filing of its Form 10-Q for the period ended June 30, 2024.
- Management is currently unable to estimate the magnitude or impact of the required restatements.
Cellectar Biosciences announced positive clinical data from its CLOVER WaM pivotal study for iopofosine I-131, meeting its primary endpoint with an 80% overall response rate. The company also disclosed a preliminary cash position of $25.9 million as of June 30, 2024.
🚩 Red Flags
- Cash position is preliminary and subject to change/material difference once financial statements are finalized.
📋 Key Facts
- CLOVER WaM study achieved an Overall Response Rate (ORR) of 80%.
- Major Response Rate (MRR) was 56.4%, significantly exceeding the primary endpoint of 20%.
- Disease Control Rate (DCR) reached 98.2% in the studied population.
- 78% of patients achieving ORR remained free from disease progression at 18 months.
- Preliminary cash and cash equivalents reported at $25.9 million as of June 30, 2024.
Cellectar Biosciences entered into inducement letters with existing warrant holders to encourage the exercise of Tranche B warrants at a reduced price. The transaction resulted in approximately $19.4 million in gross proceeds and involved the issuance of new 'Inducement Warrants' structured around clinical/regulatory milestones.
🚩 Red Flags
- Significant dilution risk: The exercise of existing warrants and issuance of new inducement warrants will result in a substantial increase in common stock share count.
- Desperation signaling: Offering reduced exercise prices ($2.52 vs potentially higher market rates) to induce cash is often used by micro-cap biotech firms facing liquidity constraints.
- Milestone-contingent dilution: The warrant expiration dates are tied directly to FDA regulatory milestones, meaning significant dilution is likely triggered upon positive clinical/regulatory news.
📋 Key Facts
- The company received aggregate gross proceeds of approximately $19.4 million.
- Existing Tranche B warrants were exercised at a reduced, as-converted common stock price of $2.52 per share.
- New 'Inducement Warrants' were issued in three tranches (A, B, and C) with exercise prices of $2.52, $4.00, and $5.50 respectively.
- Tranche A expires upon FDA assignment of a PDUFA goal date for iopofosine I 131 review or July 20, 2029.
- Tranche B expires upon FDA approval of the New Drug Application (NDA) for iopofosine I 131 or July 20, 2029.
- Tranche C expires when quarterly gross revenues from iopofosine I 131 exceed $10 million in the US or July 20, 2029.
Cellectar Biosciences has dismissed its independent auditor, Baker Tilly US, LLP, and is engaging Deloitte & Touche LLP. The dismissal follows a period where the previous auditor issued reports containing going concern uncertainties and identified material weaknesses in internal controls.
🚩 Red Flags
- Going concern language was present in previous audit reports (FY2022 and FY2023).
- Material weaknesses identified in internal controls over financial reporting.
- Auditor change occurring alongside existing material weakness disclosures.
📋 Key Facts
- Dismissed Baker Tilly US, LLP on July 8, 2024.
- Engaging Deloitte & Touche LLP for fiscal year ending December 31, 2024.
- Previous auditor (Baker Tilly) issued reports with an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern for FY2022 and FY2023.
- Management identified three material weaknesses in internal controls: fair value methodologies for Level 3 instruments, stock-based compensation recording, and segregation of duties/user access controls.
- No disagreements with the outgoing auditor regarding accounting principles or procedures were reported.
Cellectar Biosciences entered into a Second Amendment of Lease with CAMPUS 100 LLC to expand its office footprint in Florham Park, NJ. The agreement extends the lease term and increases total rentable area to 11,812 square feet.
🚩 Red Flags
- Increased long-term fixed lease obligation (approx. $2.5M in aggregate rent).
📋 Key Facts
- Entered into Second Amendment of Lease on June 20, 2024.
- Expanding leased space from 3,983 sq. ft. to a total of 11,812 sq. ft. (adding 7,829 sq. ft.).
- Lease expiration extended from April 30, 2029, to the end of the 74th Second Amendment Lease Month.
- Additional security deposit of $45,669.17 was paid; total aggregate security deposit is $69,235.25.
- Aggregate rent due under the amended lease is approximately $2,534,000.
Cellectar Biosciences, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 14, 2024. The meeting included the election of directors and approval of several shareholder proposals, including an increase to the company's stock incentive plan.
📋 Key Facts
- Stockholders approved an amendment to the 2021 Stock Incentive Plan to increase shares reserved for issuance by 7,000,000 shares.
- Asher Chanan-Khan and John Neis were elected to three-year terms as Class I directors.
- Stockholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2024.
- Stockholders approved executive compensation on a non-binding advisory basis.
Cellectar Biosciences, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024, and provided a corporate update via press release.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes results of operations and financial condition (Item 2.02).
- A corporate update was provided alongside the quarterly earnings release.
Cellectar Biosciences issued an 8-K to announce its full-year financial results for the period ending December 31, 2023, and provided a corporate update via press release.
📋 Key Facts
- Report date: March 27, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes an earnings press release (Exhibit 99.1) and interactive data files.
The company is providing an update on its share capital structure following the exercise of Tranche A warrants and other warrant exercises occurring since November 2023.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- As of January 31, 2024, common stock outstanding: 30,452,042 shares.
- Series E-2 Preferred Stock outstanding: 319.76 shares.
- Series E-3 Preferred Stock outstanding: 918.00 shares.
- Series D Preferred Stock outstanding: 111 shares.
- The update follows the exercise of Tranche A warrants and other warrant exercises since November 2023.
Cellectar Biosciences announced the full exercise of Tranche A warrants from its September 2023 financing. This resulted in gross proceeds of approximately $44.1 million for the company.
📋 Key Facts
- Tranche A warrants issued in September 2023 have been exercised in full.
- Gross proceeds from the exercise total approximately $44.1 million.
- The event occurred/was announced on January 25, 2024.
Cellectar Biosciences announced positive topline data from its pivotal CLOVER-WaM clinical trial for Iopofosine I-131 in patients with Waldenstrom’s macroglobulinemia. The study successfully achieved its primary endpoint.
📋 Key Facts
- The company reported positive topline data from the CLOVER-WaM pivotal trial on January 8, 2024.
- The clinical study focused on Iopofosine I-131 for the treatment of Waldenstrom’s macroglobulinemia.
- The trial achieved its primary endpoint.